(United States Federal Circuit) - Affirming the decision of the district court holding, after a bench trial, that the asserted claims of a patent relating to the treatment of schizophrenia with iloperidone administered based on the genotype of the patient were infringed and not invalid.
(United States Federal Circuit) - Affirming that a chemical compound that mirrored a patented chemical compound was encompassed by the description that only portrayed one of the arrangements in the claim.
(United States Federal Circuit) - Vacating the Patent Trial and Appeal Board's dismissal of an interference claim for lack of standing and remanding for further proceedings because the description of a method for removing hair using nanoparticles to damage hair follicles was a sufficient written description under the Patent Act because although the description only gave optical density rather than particles per ml, this was enough of a disclosure to convey to those skilled in the art that the inventor had possession of the claimed subject matter.
(United States Federal Circuit) - Affirming the decision of the Patent Trial and Appeal Board in an inter partes review proceeding of patents relating to boron-containing small molecules used to treat fungal infections, holding that all of the claims of a patent owned by a company were unpatentable for obviousness.
(United States Federal Circuit) - Affirmed the bench trial finding that valid patents still existed in a longstanding pharmaceutical drug called Aveed after defendant Custopharm was sued for patent infringement by Endo Pharmaceuticals and Bayer after seeking FDA approval to produce a generic version of Aveed.
(United States Federal Circuit) - Affirmed a finding of patent claim invalidity involving certain claims related to a drug distribution system for tracking prescriptions of sensitive drugs, such as those with addictive properties. In affirming, the Federal Circuit held that the Patent Trial and Appeal Board did not err and that its determination, on inter partes review, that the patents were invalid was obvious.
(United States Federal Circuit) - Affirmed that tribal sovereign immunity could not be asserted in a patent proceeding. A pharmaceutical company involved in a dispute over an eye medication patent transferred the title of its patent to a Native American tribe, which then moved to terminate the patent proceeding on the basis of sovereign immunity. Concluding that tribal sovereign immunity cannot be asserted in inter partes review, the Federal Circuit affirmed the denial of the Tribe's motion to terminate the proceeding.
(United States Ninth Circuit) - Reversed in part the dismissal of a securities fraud class action alleging that a biotechnology firm misrepresented to investors the status of a clinical drug trial. An investor brought this suit contending that the company and certain top executives violated Section 10(b) of the Securities Exchange Act of 1934. On appeal, the Ninth Circuit held that the district court erred in part in dismissing the complaint for failure to state a claim. The panel also ruled that the district court abused its discretion in judicially noticing certain facts and in incorporating certain documents into the complaint.
(United States First Circuit) - Affirmed the dismissal of two putative antitrust class actions alleging that a pharmaceutical company took steps to block the entry of generic versions of its leukemia-treatment drug into the U.S. market. The plaintiffs, including several labor union benefit funds, claimed that the drugmaker engaged in anticompetitive conduct by bringing sham infringement lawsuits against manufacturers trying to enter the market with generic versions of that drug. Dismissing the complaints, the district court held that the plaintiffs had not plausibly alleged their claims, and the First Circuit affirmed.
(United States Second Circuit) - Held that it was proper to remand to New York state court a case in which a labor union health plan sought disclosure of a patent dispute settlement agreement between pharmaceutical companies and the generic manufacturer of the EpiPen. Affirmed the district court's remand order, in this special proceeding under New York law seeking pre‐action disclosure.
(United States Supreme Court) - Held that an inventor's sale of an invention to a third party who is obligated to keep the invention confidential can qualify as prior art for purposes of determining the patentability of the invention. The dispute here involved two pharmaceutical companies that disagreed about whether a certain drug was under patent; one of the companies wanted to market a generic version of it. Justice Thomas delivered the unanimous opinion.
Iedereen die voor een B2B-bedrijf Google-zoekadvertenties inzet herkent het wel. Voor relevante zoekwoorden die dicht bij een conversie staan, betaal je een hoge CPC. Om dit te omzeilen kiezen veel adverteerders voor brede zoekwoorden, maar dat levert ook irrelevante klikken op van consumenten die je niet wil aantrekken. Nu komt Google met B2B search audiences: […]
(United States Supreme Court) - Held that the federal rule governing appeals from orders granting or denying class certification is not subject to equitable tolling. The plaintiff contended that his failure to comply with the 14-day limit specified in Federal Rule of Civil Procedure 23(f) should be tolled, because he had acted reasonably in the particular circumstances here. Disagreeing, the U.S. Supreme Court declared that the time limit for appealing class certification rulings cannot be equitably tolled. Justice Sotomayor wrote the unanimous opinion.
"Whiskey And Cigarettes" Country Radio Show, In Association With The European Academy Of Country Music (EACM) Has Announced Their Top 30 Of 2018 Year-end Chart. The Show Is Syndicated On More Than 25
(United States Seventh Circuit) - Held that a manufacturer breached its contractual agreement with a distributor in the medical-supply industry. Affirmed a bench trial judgment, in a case involving distribution rights to a special type of hospital bed.
Stock Broker-turned-entrepreneur Alan Chan Sets Sights On Investing In Not Just Kpop, But The "Asian Pop" Entertainment Business
Laguna Beach Singer/guitarist Awarded Recording Time With Orange County Production House
Nervosa guitarist Prika Amaral has announced a brand new lineup for the band, which has now become a quartet following the breakup of the previous trio lineup.
(United States Fifth Circuit) - Held that energy companies emerging from bankruptcy did not have to pay certain creditors a contractual make-whole amount, even though the companies were now solvent due to a rise in commodity prices. Vacated and remanded.
Tune in at 8pm to hear Francesco Cilea's Adriana Lecouvreur staring Renata Tebaldi and Mario del Monaco recorded in 1962.
They're trying to reschedule.
The post RAMMSTEIN Officially Cancels European Stadium Tour 2020 appeared first on Metal Injection.
(United States Second Circuit) - Vacated and remanded. A complaint alleging claims for forced labor and human trafficking in violation of the Trafficking Victims Protection Act was improperly dismissed because the plaintiff plausibly stated claims.
(United States Ninth Circuit) - Affirmed the dismissal of a private antitrust action brought by consumers seeking to enjoin the largest U.S. beer producer from acquiring the second largest. The consumers argued in this action brought under section 7 of the Clayton Act that the merger would lessen competition in the U.S. beer market. Concluding that they failed to state a claim, the Ninth Circuit emphasized that the U.S. Department of Justice, as a condition of approving the merger, had required the company being acquired to divest entirely its domestic beer business.
(United States First Circuit) - Affirmed the dismissal of two putative antitrust class actions alleging that a pharmaceutical company took steps to block the entry of generic versions of its leukemia-treatment drug into the U.S. market. The plaintiffs, including several labor union benefit funds, claimed that the drugmaker engaged in anticompetitive conduct by bringing sham infringement lawsuits against manufacturers trying to enter the market with generic versions of that drug. Dismissing the complaints, the district court held that the plaintiffs had not plausibly alleged their claims, and the First Circuit affirmed.
(United States First Circuit) - Affirmed the dismissal of two putative antitrust class actions alleging that a pharmaceutical company took steps to block the entry of generic versions of its leukemia-treatment drug into the U.S. market. The plaintiffs, including several labor union benefit funds, claimed that the drugmaker engaged in anticompetitive conduct by bringing sham infringement lawsuits against manufacturers trying to enter the market with generic versions of that drug. Dismissing the complaints, the district court held that the plaintiffs had not plausibly alleged their claims, and the First Circuit affirmed.
Not to suggest the Broncos and John Elway got lucky with the 15th pick in the NFL draft, but when Denver was on the clock, any Goober could’ve screamed the obvious choice:
When FanDuel asked, Will the Broncos Make the Playoffs?, 97% of the weekend action among Colorado bettors was on “Yes.” These days, if you can’t trust your heart, trust your gut.
NEW YORK — Major League Baseball will cut its amateur draft from 40 rounds to five this year, a move that figures to save teams about $30 million. Clubs gained the ability to reduce the draft as part of their March 26 agreement with the players’ association and MLB plans to finalize a decision next […]
When FanDuel asked, Will the Broncos Make the Playoffs?, 97% of the weekend action among Colorado bettors was on “Yes.” These days, if you can’t trust your heart, trust your gut.
| Bermuda’s Tyler Smith has competed in the 2019 Malmö ETU Sprint Triathlon European Cup in Sweden, finishing 28th in a field of 71 starters. Smith clocked a time of 55.29, finishing one minute and thirty-three seconds behind the winner Constantine Doherty from Ireland. He recorded a time of 9:18 on the swim, then clocked 29:28 on […] |